Summary & Overview
HCPCS J9298: Injection, Nivolumab and Relatlimab-rmbw, 3 mg/1 mg
HCPCS Level II code J9298 represents an injectable combined immunotherapy product — nivolumab and relatlimab-rmbw — billed per unit of 3 mg/1 mg. This code matters nationally as it captures administration and product utilization for a novel combination immunotherapy regimen used in oncology, with implications for specialty pharmacy distribution, infusion staffing, and payer coverage policies.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J9298 is used in clinical practice, typical sites of service, and the payer landscape affecting access and coverage. The publication also summarizes benchmarking metrics where available, relevant policy updates affecting billing and reimbursement for combination biologics, and clinical context related to infusion-based oncology treatments.
The guide is intended for revenue cycle managers, oncology practice administrators, and policy analysts seeking a national view of billing and coverage considerations for this combination immunotherapy product. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9298 describes an injection of nivolumab and relatlimab-rmbw, with the unit quantity defined as 3 mg nivolumab / 1 mg relatlimab-rmbw. This code represents a combined immunotherapy product used in oncology treatment regimens.
Service Type: Injectable biologic therapy
Typical Site of Service: Hospital outpatient infusion center or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
A 63-year-old patient with unresectable or metastatic melanoma presents to the oncology infusion suite for administration of combination immunotherapy. The clinician has ordered J9298 (injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg) as part of first-line systemic therapy. The patient is registered at the infusion center, vital signs are obtained, chemotherapy consent and allergy review are confirmed, and medication reconciliation is completed. A certified oncology pharmacist or registered nurse verifies the prescribed dose, inspects the infusion bag, and programs the infusion pump. The dose is administered intravenously per protocol over the recommended infusion time while the patient is monitored for infusion-related reactions and immune-mediated adverse events. Post-infusion, the patient is observed for a defined interval, provided discharge instructions about symptoms of immune-related toxicity (such as pneumonitis, colitis, hepatitis, endocrinopathies), and scheduled for follow-up visits and laboratory monitoring (including liver function tests, thyroid function, and complete blood count). Billing for the drug uses the HCPCS Level II code J9298 and may include appropriate modifiers to reflect circumstances such as administration location, partial administration, or shipment/handling situations. The typical site of service is an outpatient oncology clinic or hospital outpatient infusion center. The typical patient scenario involves adults with advanced melanoma or other approved indications receiving combination checkpoint inhibitor therapy under oncologist supervision.
Coding Specifications
| Modifier | Description | When to Use |
|---|